

Addendum

Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series**Kevin Drenner^{1,*}, Gargi D. Basu^{2,*}, Laurie J. Goodman², Audrey A. Ozols², Janine R. LoBello², Thomas Royce², Michael S. Gordon³, Erkut H. Borazanci³, Margaux A. Steinbach³, Jeffrey Trent¹ and Sunil Sharma¹**¹Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA²Ashion Analytics, LLC, Phoenix, AZ 85004, USA³HonorHealth Research Institute, Scottsdale, AZ 85258, USA

*These authors contributed equally to this work

Published: October 20, 2022**Copyright:** © 2022 Drenner et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**Consent was added to this article:** The study, protocol # HRI-0029 is an IRB approved clinical study, WIRB # 20182804, and all patients signed informed consent to participate.Original article: Oncotarget. 2021; 12:1836–1847. <https://doi.org/10.18632/oncotarget.28046>